🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06306183
Recruiting Not applicable

Effect of Vitamin C on Pain Reduction After an Emergency Department Visit

NCT06306183 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2026-03-02

Condition(s) studied

Pain, Acute

Investigational drug(s) / intervention(s)

Vitamin CPlacebo

Vitamin C: 900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.

Placebo: Placebo taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.

Study summary

Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. Because of these limits, some patients receive opioids, which can cause side effects and carry a risk of dependence. Safer and more accessible options are needed.

Vitamin C is widely known for supporting the immune system, but research suggests it may also help reduce pain and inflammation. Studies in surgical patients have shown that vitamin C can lower pain levels, reduce the need for opioids, and support healing. These effects may be linked to its antioxidant properties and its role in tissue repair. However, no study has tested whether vitamin C can help people with recent MSK injuries treated in the emergency department.

The VICAMED study aims to answer this question. Adults arriving with an MSK injury that occurred within the past 48 hours can participate if they have at least moderate pain. Participants are randomly assigned to receive either vitamin C or a placebo. The first dose is given in the emergency department, followed by twice daily capsules for three days. Pain is measured using a simple 0-100 scale, recorded in an electronic or paper diary. A follow-up on day six helps the research team understand each participant's recovery, medication use, and overall experience.

Vitamin C is inexpensive, widely available, and very safe at the doses used in this study. If it proves effective, it could offer a simple, low risk option to help patients manage pain after an MSK injury and reduce the need for opioids in emergency care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years old 2. Presenting to the ED with acute MSK pain of ≤ 48 hours duration at triage 3. Verbal numerical rating scale pain intensity at triage of ≥ 4 on a 0-10 scale 4. Triaged to the ambulatory section of the ED 5. Able to communicate in French or English Exclusion Criteria: 1. Usage of Vit C supplements in the last week 2. Active cancer 3. Treated with opioids for any pain within 24 hours prior to recruitment 4. Treatment for chronic pain 5. Unable to fill out a pain intensity diary or unavailable for follow-up 6. Allergy to milk (lactose in the placebo) or Vit C 7. Treated with cyclosporine or warfarin 8. Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis 9. Hospitalized after clinician evaluation

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
The Ottawa Hospital - General and Civic Campus Ottawa Ontario Not Yet Recruiting
Hôtel-Dieu de Lévis Lévis Quebec Not Yet Recruiting
Hopital du Sacre-Coeur de Montreal Montreal Quebec Recruiting
CHU de Québec - Université Laval Québec Quebec Not Yet Recruiting

More Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06306183 on ClinicalTrials.gov ↗ ← All trials in Canada